Luteinizing hormone-releasing hormone agonists versus orchiectomy in the treatment of prostate cancer: A systematic review

BackgroundOrchiectomy has been replaced by medication represented by luteinizing hormone-releasing hormone (LHRH) agonist as the first-line therapy for androgen deprivation therapy (ADT). After the wide application of LHRH agonist, the side-effects of long-term ADT were noticed. It is time to reconsider the role of medication and surgeries in the treatment of prostate cancer.MethodsEmbase, Pubmed, Web of science and Cochrane library were searched for relevant trials. Quality of the studies and risk of bias were assessed by using the Newcastle-Ottawa Scale (NOS). Therapeutic and adverse effects, as well as long-term metabolic adverse effects were extracted from the selected studies. The data synthesized in meta-analyses were performed with R software (4.2.1). Risk ratio (RR) with its 95% confidence interval (CI) was calculated by combining outcome data including complete and partial response rate, progression rate, death rate and adverse effects such as hot flash and increase in pain. Descriptive analysis was performed among the prostate specific antigen (PSA), testosterone and metabolic adverse effects due to a lack of homogeneity of frailty measures.Results1,711 participants from 11 studies were included in our systematic review. 1,258 patients from six studies were included in the meta-analysis. Based on the meta-analysis, the therapeutic and adverse outcomes included overall response rate, complete response rate, partial response rate, stable rate, progression rate, death rate and hot flashes. No statistical significance was observed between LHRH agonists and orchiectomy. Compared with surgery, LHRH agonist elevated the risk of the increase in pain. In descriptive analysis, it was shown that the therapeutic effects between PSA and testosterone also showed no significant difference. Both groups had lipid and glucose metabolic disorders, and a few studies reported worse lipid metabolic performance in orchiectomy group and worse insulin resistance in LHRH agonist group.ConclusionWe found that the therapeutic outcomes were similar between the two options. The results of lipid and glucose metabolic abnormality were controversial in existing studies. The direct comparison studies on metabolic adverse effects should be performed in the future. The therapeutic, metabolic, psychological and economical effects should be considered before applying ADT methods.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/, identifier CRD42022365891

Transient Pulmonary Atelectasis after Ketamine Sedation during Cardiac Catheterization in Spontaneously Breathing Children with Congenital Heart Disease

Background: Ketamine is applied widely for sedation during cardiac catheterization in spontaneously breathing children with congenital heart disease (CHD). However, a rare and unreported respiratory complication, transient and reversible atelectasis of lungs (TRAL), was identified. Purpose: The study was performed to investigate retrospectively the prevalence and clinical characteristics of TRAL after ketamine sedation in pediatric cardiac catheterization. Methods: Four thousand four hundred and seventy-four sick children were sedated with ketamine, and pediatric cardiac catheterization was carried out under spontaneous breathing. TRAL was detected in 33 children (17 M/16 F, age was 2.1±1.7 years) by retrospective analysis. The clinical and radiographic characteristics were recorded before, during and after TRAL. Results: In pediatric cardiac catheterization, the prevalence of TRAL was 0.74% after ketamine sedation. TRAL occurred in 23 children with cyanotic CHD, and 10 with acyanotic CHD. All TRALs had common clinical and radiographic features: the diffuse opacity of bilateral lungs developed rapidly (identified under X-ray fluoroscopy), associated with decrease in lung volume, and then the decrease in SpO2 (94.2±9.2% vs. 59.4±2.2%, P<0.05), and heart rates (143.5±14.3 bpm vs. 58.3±9.7 bpm, P<0.05) followed quickly. TRAL was relieved by supportive oxygen in 32 children (23 with face mask, and 9 with endotracheal intubation), and the duration of TRAL was 1.6±0.5 minutes. However, TRAL caused the death of one child. Conclusions: TRAL is a rare and urgent respiratory complication after ketamine sedation, and the mechanism is unclear. Rapid and diffuse opacity of bilateral lungs is the earliest sign of TRAL in pediatric cardiac catheterization, and the immediate supportive oxygen is crucial

The first clinical data of the SAPIEN 3 aortic valve in the treatment of aortic stenosis in China

BackgroundData on outcomes following transcatheter aortic valve replacement with SAPIEN 3 in China is limited as it was approved by the National Medical Products since 2020. The present study was designed to collect clinical data on the SAPIEN 3 aortic valve in Chinese patients with bicuspid aortic valve and tricuspid aortic valve stenosis.MethodsWe analyzed the patient characteristics, procedural features and procedural outcomes of the first 438 patients (223 for bicuspid aortic valve and 215 tricuspid aortic valve) from 21 provinces in 74 sites treated with the SAPIEN 3 valve system for transcatheter aortic valve replacement between September 2020 and May 2022.ResultsProcedural mortality was 0.7%. 5 cases during the operation were converted to surgery. Among 438 cases, permanent pacemaker implantation was performed in a total of 12 cases (2.7%). The patient had severe leaflet calcification of the aortic valve, with moderate and severe calcification reaching 39.7% and 35.2% respectively. The size of the implanted valves was predominantly 26 mm and 23 mm, reaching 42.5% and 39.5% respectively. The incidence of moderate or severe perivalvular leak in the postoperative period was 0.5%, with a predominance of 90/10 and 80/20 valve deployment height. There was a significant difference in the deployment height of the valve between bicuspid aortic valve and tricuspid aortic valve, with the bicuspid aortic valve having a more deployment height of 90/10. Annulus size in bicuspid aortic valve group was significantly larger than tricuspid aortic valve group. Valve sizing for oversized, within size, and undersized were different between bicuspid aortic valve and tricuspid aortic valve.ConclusionsProcedural success rates were high, with similar and good results for bicuspid aortic valve and tricuspid aortic valve, low perivalvular leak for both valve types, and low permanent pacemaker implantation rates for both valve types. Annulus size, valve sizing and coronary artery height were significantly different in the BAV and TAV group

In vitro bench testing using patient-specific 3D models for percutaneous pulmonary valve implantation with Venus P-valve

Background: Due to the wide variety of morphology, size, and dynamics, selecting an optimal valve size and location poses great difficulty in percutaneous pulmonary valve implantation (PPVI). This study aimed to report our experience with in vitro bench testing using patient-specific three-dimensional (3D)-printed models for planning PPVI with the Venus P-valve. Methods: Patient-specific 3D soft models were generated using PolyJet printing with a compliant synthetic material in 15 patients scheduled to undergo PPVI between July 2018 and July 2020 in Central China Fuwai Hospital of Zhengzhou University. Results: 3D model bench testing altered treatment strategy in all patients (100%). One patient was referred for surgery because testing revealed that even the largest Venus P-valve would not anchor properly. In the remaining 14 patients, valve size and/or implantation location was altered to avoid valve migration and/or compression coronary artery. In four patients, it was decided to change the point anchoring because of inverted cone-shaped right ventricular outflow tract (RVOT) (n = 2) or risk of compression coronary artery (n = 2). Concerning sizing, we found that an oversize of 2-5 mm suffices. Anchoring of the valve was dictated by the flaring of the in- and outflow portion in the pulmonary artery. PPVI was successful in all 14 patients (absence of valve migration, no coronary compression, and none-to-mild residual pulmonary regurgitation [PR]). The diameter of the Venus P-valve in the 3D simulation group was significantly smaller than that of the conventional planning group (36 [2] vs. 32 [4], Z = -3.77, P &lt;0.001). Conclusions: In vitro testing indicated no need to oversize the Venus P-valve to the degree recommended by the balloon-sizing technique, as 2-5 mm sufficed.</p

Transient Pulmonary Atelectasis after Ketamine Sedation during Cardiac Catheterization in Spontaneously Breathing Children with Congenital Heart Disease

Background: Ketamine is applied widely for sedation during cardiac catheterization in spontaneously breathing children with congenital heart disease (CHD). However, a rare and unreported respiratory complication, transient and reversible atelectasis of lungs (TRAL), was identified. Purpose: The study was performed to investigate retrospectively the prevalence and clinical characteristics of TRAL after ketamine sedation in pediatric cardiac catheterization. Methods: Four thousand four hundred and seventy-four sick children were sedated with ketamine, and pediatric cardiac catheterization was carried out under spontaneous breathing. TRAL was detected in 33 children (17 M/16 F, age was 2.1±1.7 years) by retrospective analysis. The clinical and radiographic characteristics were recorded before, during and after TRAL. Results: In pediatric cardiac catheterization, the prevalence of TRAL was 0.74% after ketamine sedation. TRAL occurred in 23 children with cyanotic CHD, and 10 with acyanotic CHD. All TRALs had common clinical and radiographic features: the diffuse opacity of bilateral lungs developed rapidly (identified under X-ray fluoroscopy), associated with decrease in lung volume, and then the decrease in SpO2 (94.2±9.2% vs. 59.4±2.2%, P<0.05), and heart rates (143.5±14.3 bpm vs. 58.3±9.7 bpm, P<0.05) followed quickly. TRAL was relieved by supportive oxygen in 32 children (23 with face mask, and 9 with endotracheal intubation), and the duration of TRAL was 1.6±0.5 minutes. However, TRAL caused the death of one child. Conclusions: TRAL is a rare and urgent respiratory complication after ketamine sedation, and the mechanism is unclear. Rapid and diffuse opacity of bilateral lungs is the earliest sign of TRAL in pediatric cardiac catheterization, and the immediate supportive oxygen is crucial